Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.
The company said investors can access the Roivant (Nasdaq: ROIV) conference call by phone after registering online and can view the presentation and live webcast via the Investors > News & Events section at https://www.immunovant.com/investors/news-events/ir-calendar. An archived webcast will be available on Immunovant’s website after the call.
Positive
- None.
Negative
- None.
News Market Reaction 51 Alerts
On the day this news was published, IMVT gained 2.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.9% during that session. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $95M to the company's valuation, bringing the market cap to $3.80B at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When will Immunovant (IMVT) release Q2 2025 financial results and hold its business update?
How can investors join the Immunovant (IMVT) conference call on November 10, 2025?
Where will the Immunovant (IMVT) webcast and presentation be posted?
Will Immunovant (IMVT) make a recording of the November 10, 2025 call available?
Does the announcement mention any earnings figures or guidance for IMVT for Q2 2025?
